Opioid use in palliative care by Hosking, M
Prejudice, fear and lack of core knowledge
contribute to present-day poor opioid
administration by doctors caring for
patients with intolerable symptoms and
pain at the end of life.The core knowl-
edge required for using opioids is relative-
ly simple, but myths and misconceptions
regarding morphine still abound in both
medical and patient communities. In this
article an attempt is made to overcome
some of these barriers to good symptom
management.
INDICATIONS FOR OPIOIDS IN
PALLIATIVE CARE
Opioids are primarily used to relieve
symptoms of pain and dyspnoea and fre-
quently will also reduce distressing cough
and diarrhoea.Their use for the allevia-
tion of terminal restlessness and the
induction of sedation is unacceptable.
Such practices only perpetuate and rein-
force inaccurate beliefs and prejudice
regarding opioid analgesics. This may ulti-
mately result in their under-utilisation
with subsequent poor terminal symptom
control.
CHOICE OF OPIOID
Opioids are divided into those with strong
and those with weak agonist effects on
opiate receptors. I will discuss only the
opioids available in South A f rica (Table I).
Morphine is the opioid drug of choice; it
is versatile, affordable and readily avail-
able. It is administered orally and has a
half-life of about 2 - 2.5 hours. Except in
patients in renal failure, it has no danger
of accumulation.
With regard to the choice of opioids in
palliative care, the pertinent characteris-
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Opioid use in palliative
care
The confident and safe use of opioids in 
palliative care is an essential skill required by all
d o c t o r s .
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The core knowledge
required for using opi -
oids is relatively simple,
but myths and miscon -
ceptions regarding mor -




• Morphine • Tramadol (Tramal, TramaHexal)                         
• Fentanyl  (Duragesic) • Codeine





• Pentazocine (Ospronim, Sosenol)
Table I. Opioid choices
tics of each drug are highlighted
below.
Transdermal fentanyl causes less
constipation and dysphoria than
morphine and accumulates less in
uraemic patients. However, it is
prohibitively expensive for regular
use.
Methadone is not available in
South Africa in high enough con-
centrations for regular oral use. It
does have unique characteristics,
making it useful in some mor-
phine-intolerant patients (very
uncommon). Also, it may be more
useful in neuropathic-mediated or
inflammatory pain syndromes. It
has variable pharmacokinetics
(half-life up to 10 times longer
than that of morphine), making it
particularly difficult to titrate for
chronic use.
Pethidine is not indicated for reg-
ular prolonged use in pain control
as its metabolite, norpethidine,
accumulates quickly, causing cen-
tral nervous system side-effects
such as tremors, multifocal
myoclonus and even seizures.
Buprenorphine displaces mor-
phine from opioid receptors and
may potentiate opioid withdrawal
symptoms if given in addition to
morphine. It has a half-life of 8
hours and may be administered
sublingually. A higher incidence of
side-effects, such as nausea and
confusion, is often encountered.
Dipipanone is only available com-
bined with cyclizine (Wellconal),
leading to excessive anticholinergic
and sedation side-effects with dose
increase.
Pentazocine has a higher inci-
dence of side-effects, including
thought disturbances and halluci-
nations if compared with regular
morphine.
Tramadol is as potent as pethi-
dine parenterally, but orally only as
effective as codeine.
Codeine causes more constipation
than morphine at equal analgesic
doses.
Propoxyphene is less potent than
codeine; however, it is more effec-
tive if used regularly.
MORPHINE
No other strong opioid shows any
clear advantage over morphine.
Morphine is versatile and can be
prescribed orally in solution (mist
morphine), or in tablet form (slow-
release formulations). Morphine is
also well tolerated parenterally
(intramuscular, subcutaneously,
intravenously, and intrathecally).
General strategies for initiating
doses, increasing doses and chang-
ing formulations will be discussed
below, as well as the management
of common opioid side-effects.The
guidelines for complex pain syn-
dromes or the management of opi-
oid-insensitive pain are not dis-
cussed here. Guidance in these sit-
uations may best be obtained in
other literature or by consultation
with pain specialists or skilled pal-
liative physicians.
Starting morphine
It is usual to start morphine orally
and best to use the mist morphine
formulation as it has a shorter half-
life (2 - 2.5 h) compared with
other slow-release formulations.
This facilitates faster assessment of
pain response to dosing, giving a
steady state faster than formula-
tions with longer half-lives. Mist
morphine is bitter and may be
flavoured with fruit juice or milk.
The starting dose varies according
to the age of the patient, the severi-
ty of pain and the availability of the
patient for ongoing clinical review.
Start the elderly and frail with 2.5
mg and other patients with 5 mg.
The dosing interval should be
every 4 hours (to maintain steady-
state drug levels). ‘As required’ or
longer dose intervals will result in
poor pain control and possibly
even in an increase in side-effects.
The 4-hourly dosing interval does
not necessarily mean that patients
must be woken every 4 hours dur-
ing the night.This is overcome by
doubling the last ‘retiring’ dose,
which facilitates better patient
sleep and a longer steady state of
drug level until the morning, when
the patient awakes and 4-hourly
dosing is resumed.
The following is an example of the
first prescription: mist morphine
10 mg/5 ml; dose: 2.5 ml q4h, 5 ml
nocte on retiring.
Increasing the dose of morphine
Doses need to be reviewed regular-
ly and increased as dictated by
pain. Side-effects do recur at times
of dose increase and need to be
planned for and actively managed.
Doses of morphine every 4 hours
are increased by 50% above the
previous prescribed dose if pain is
not adequately controlled, e.g.
5 mg becomes 7.5 mg and 100 mg
becomes 150 mg.
Lower dose increments will be
ineffective in managing increasing
pain. In exceptional cases mor-
phine doses may be increased over
time to greater than 500 mg 4-
hourly, as long as side-effects are
attended to.
The following is an example of a
change in prescription when
increasing the dose (50%) and lim-
iting regular dose volumes: Mist
morphine 10 mg/5 ml; dose 10 ml
q4h becomes mist morphine 
100 mg/5 ml; dose 1.5 ml q4h.
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Dose morphine by the mouth
and by the clock, attending to
side-effects from the first dose.
Essential pharmacology
Morphine is well absorbed from
the gastrointestinal tract and
metabolised in the liver to mor-
phine-6-glucuronide.The metabo-
lite morphine-6-glucuronide is
more potent as an analgesic than
morphine, and also reaches higher
blood levels an hour after oral
ingestion than morphine.The
metabolites are excreted primarily
by the kidneys and may accumu-
late in patients with renal impair-
ment. Opioid toxicity is seen in
renal impairment but not in severe
liver failure. Occasionally pretermi-
nal coma patients on opioids may
become more restless, with
myoclonic jerks, as death
approaches.The clinician mistak-
ing these symptoms for pain may
increase the morphine dose (not
recognising the early signs of opi-
ate toxicity aggravated by accumu-
lation of morphine metabolites
because of prerenal failure) and




The side-effects of opiates/mor-
phine are listed in Table II.
Constipation is nearly always
encountered and needs aggressive
management from the first dose of
opioid prescribed. Cancer patients
tolerate bulking agents poorly, as
they struggle to maintain adequate
intake of fluids to stimulate bowel
motility. The best option is a com-
bination of a stool softener and a
bowel stimulant, e.g. liquid paraffin
or sorbitol with senna.
Nausea and vomiting will be
encountered in at least 30% of
patients, but usually decrease in
most patients within a few days.
Recurrence of nausea must be
expected if the morphine dose is
increased.The mechanism of nau-
sea is produced predominantly
centrally via dopamine effects in
the chemoreceptor trigger zone in
the floor of the 4th ventricle and
occasionally peripherally by delay-
ing gastric motility. The dopamine
antagonist haloperidol 1.5 mg daily
or metoclopramide 10 mg three
times daily is usually adequate to
overcome this troublesome side-
effect.
Sedation is commonly experi-
enced. It is usually mild (dropping
off in a light doze if unstimulated).
Often patients have had depleted
sleep because of uncontrolled pain
and may need more sleep to ‘catch
up’ after the opioid has controlled
the pain. Patients must be reas-
sured that the drowsiness will
decrease after a number of days. It
may return, to fade again, at times
of dose increase. Sedation has
many causes and may include
other drug interactions or a change
in disease process.
Confusion may be caused or
aggravated by opiates. It is usually
dose dependent, but one must look
for other reversible factors or pos-
sibly even change the opioid.
Respiratory depression is rare if
the dose is increased according to
the protocols discussed above. One
must be alert to opioid-insensitive
pain — ‘increasing drowsiness with
no improvement in pain control’.
Opioids are used successfully and
safely to relieve dyspnoea and
cough in respiratory distress!
Useful tips with morphine
Breakthrough pain is rarely con-
stant and at times extra morphine
may be required for short periods.
It is usual to recommend that the
p atient takes an extra dose (1/2 u s u a l
4-hourly dose) in these situations.
If the regular dose is 20 mg 4-
hourly, an extra dose of 10 mg may
be taken at any time if the pain is
not adequately controlled.This
may be repeated at any time during
the day. If the patient is using regu-
lar breakthrough doses, increasing
the regular maintenance dose
should be considered.
Calculate 24-hour opioid con -
sumption. This is helpful if one
needs to:
• change the type of opioid used
(charts are available to convert to
a different opioid for equal anal-
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Commonly experienced Less commonly experienced
• Constipation • Dry mouth
• Nausea and vomiting • Sweating
• Sedation • Myoclonus













patients within a few
d a y s .
The hand that writes the pre-
scription for opioids must write
the script for the aperients.
gesic potency) 
• change to using a syringe driver
(24 hour subcutaneous infusion
of medication) (discussed below)
• change mist morphine (oral) to
slow-release morphine (oral).
The regular dose of mist morphine
30 mg every 4 hours (oral) equates
to a 24-hour dose of 180 mg of
morphine (oral).Therefore one
would add 90 mg of morphine sul-
phate to the syringe driver over 24
hours (6 ampoules of 15 mg/ml)
for a subcutaneous infusion.
Use morphine to suppress
cough and dyspnoea at doses
lower than those required for treat-
ment of pain.
Re-evaluate doses regularly .
Psychological addiction to mor-
phine does not occur if it is pre-
scribed for pain relief.
Physical dependence does occur,
and if for some reason the need for
opioids decreases then the depen-
dence is always managed success-
fully by a 25% daily dose decrease
every 3 - 4 days.
Pa tient education. The success
of opioid prescribing and pain
control is directly related to how
well doctors educate patients and
prepare them for the side-effects,
and how successfully the latter can
be controlled. Many brochures are
available free of charge.
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ORAL MORPHINE —
INFORM AT ION FOR
PAT IENTS AND FA MIL IES 
Morphine is obtained from the
juice of the opium poppy and acts
on pain centres in the brain and
spinal cord. Millions of people have
used morphine for pain after surgi-
cal operations and for pain caused
by cancer. Some patients need to
take it for years and others for only
a few days.
It is used to relieve pain, so improv-
ing one’s quality of life.There is no
upper limit to the dose of morphine
that one may take.The dose of
morphine may also safely be
decreased if one’s pain declines in
intensity. Many people fear addic-
tion to morphine. One does not
become addicted to morphine, but
one does need to decrease its
administration slowly under super-
vision if it is no longer necessary.
This occurs without any adverse
effects.
Your doctor will supervise your
dose of morphine. Your pain is usu-
ally ongoing and therefore you
would need to take morphine 
regularly by the clock.
Morphine does have side-effects
including constipation, nausea and
vomiting and some drowsiness. In
most cases these side-effects are
easily overcome and successfully
managed.They also tend to
decrease after a few days of taking
morphine. Discuss these effects
with your doctor.You would need
to take medicine regularly to over-
come the constipation.
One’s pain is rarely constant and
may increase for short periods.Your
doctor will decide how much extra
morphine you may take during this
period.
If you feel that the morphine or
your pain is not under control,
please feel confident to discuss it
with your doctor or specialist.
Others who may be able to help
may include hospice-trained staff
(nursing or medical), pain special-
ists or cancer nursing organisations.
Help is only a call away.
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The confident use of morphine in
palliative care requires core
knowledge of its pharmacology
and a confident understanding of
the strategies to increase the
dose. 
Dose by the mouth and by the
clock.
The hand that writes the script
must attend to constipation and
have a strategy for nausea con-
trol.
If pain is not controlled or
improved by 2 - 3 dose increases
it is probably a partially opioid-
insensitive pain. Consider the use
of co-analgesics.
Good patient preparation and
proper opioid use can only
remove present prejudice and
fear for patients and doctors
alike.
Parenteral doses of morphine are
twice as potent as oral doses.
